Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Zimmer Biomet Holdings Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.25 (market cap $1.93B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.8× Abrdn Physical Platinum Shares ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PPLT | ZBH | |
|---|---|---|
Market Cap | $1.93B | $16.95B |
Volume | 1,698,523 | 2,505,240 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $103.98 |
52-Week Low | $13.73 | $79.58 |
Typical Hold Time | 42 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.82 with a slight 0.27% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights platinum's underperformance relative to other precious metals, with some analysts seeing potential for catch-up trades while others point to bearish term structure signals.
The outlook remains cautious with bearish technicals offset by potential mean reversion opportunities. Key risks include platinum supply dynamics and precious metals market rotation. Investment opportunity exists if platinum regains momentum, but current technical weakness suggests near-term pressure.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
